TrialNature communications2025

Ligand-activated EGFR/MAPK signaling but not PI3K, are key resistance mechanisms to EGFR-therapy in colorectal cancer.

Xueping Qu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.